YD Bio Limited (YDES)
NASDAQ: YDES · Real-Time Price · USD
3.210
-0.660 (-17.05%)
Aug 28, 2026, 12:10 PM EDT - Market open
YD Bio Revenue
In the year 2024, YD Bio had annual revenue of $510.36K with 45.76% growth. YD Bio had revenue of $142.69K in the quarter ending December 31, 2024, with 95.63% growth.
Revenue (ttm)
$510.36K
Revenue Growth
+45.76%
P/S Ratio
533.23
Revenue / Employee
n/a
Employees
n/a
Market Cap
225.73M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 510.36K | 160.23K | 45.76% |
| Dec 31, 2023 | 350.13K | -13.99K | -3.84% |
| Dec 31, 2022 | 364.12K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
YDES News
- 3 days ago - YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute - GlobeNewsWire
- 4 weeks ago - YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada - GlobeNewsWire
- 5 weeks ago - YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services - GlobeNewsWire
- 2 months ago - YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations - GlobeNewsWire
- 4 months ago - YD Bio Limited Reports Full Year 2025 Financial Results - GlobeNewsWire
- 5 months ago - YD Bio Ltd trading halted, volatility trading pause - TheFly
- 5 months ago - YD Bio Ltd trading resumes - TheFly
- 5 months ago - YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States - GlobeNewsWire